Observational studyArthritis & rheumatology (Hoboken, N.J.)2019
Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.
Observational study in Arthritis & rheumatology (Hoboken, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 57 citations in OpenAlex.
- The evolving landscape of complement therapeutics in rheumatology.Annals of the rheumatic diseases · 2026Review
- Longitudinal multiomic and spatial transcriptomic profiling of lupus nephritis progression in a murine model.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Complement diagnostics and therapeutics for the pediatric population: early successes and opportunities for further advancement.Frontiers in pharmacology · 2026Review
- C3d Complement Activation and Antibody Immunity in Convalescent COVID-19: Insights From Adults and Children.Journal of immunology research · 2026Article
- Differential complement pathways and components in the clinical spectrum of systemic lupus erythematosus.Arthritis research & therapy · 2025Article
- Update in the diagnosis of complement-mediated thrombotic microangiopathy/atypical hemolytic uremic syndrome.Hematology. American Society of Hematology. Education Program · 2025Review
- Systemic lupus erythematosus as the paradigm for understanding the complex immune relationships and therapeutic opportunities for targeting complement in autoimmune diseases.Immunobiology · 2025Review
- Urinary V-Set Ig Domain-Containing Protein 4 and Immune Complexes for Tracking Lupus Nephritis and Renal Pathology.ACR open rheumatology · 2025Article
- [What is proven in the treatment of complement-mediated kidney diseases?]Innere Medizin (Heidelberg, Germany) · 2024Review
- Multiorgan involvement and circulating IgG1 predict hypocomplementaemia in IgG4-related disease.Annals of the rheumatic diseases · 2024Article
- Article
- Complement Activation in Nephrotic Glomerular Diseases.Biomedicines · 2024Review
- Differentiating between activation via the lectin or the classical complement pathway in patients with systemic lupus erythematosus.Clinical and experimental immunology · 2023Article
- The role of complement in kidney disease.Nature reviews. Nephrology · 2023Review
- Differences in Physico-Chemical Properties and Immunological Response in Nanosimilar Complex Drugs: The Case of Liposomal Doxorubicin.International journal of molecular sciences · 2023Article
- Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry.RMD open · 2023Article
- C3dg and MAC complement depositions in the renal histopathology of patients with lupus nephropathy.Translational pediatrics · 2023Article
- Serum cystatin C and βeta-2 microglobulin as potential biomarkers in children with lupus nephritis.Archives of rheumatology · 2023Article
- Complement as a Biomarker for Systemic Lupus Erythematosus.Biomolecules · 2023Review
- Inter-Individual Variations: A Challenge for the Standardisation of Complement Activation Assays.International journal of nanomedicine · 2023Review
Corrections and comments
- Commented on by
- Commented on byReply.2019
- Commented on by
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
objectiveTo examine correlations between blood levels of complement split product iC3b and serum component C3 with clinically meaningful changes in disease activity in patients with systemic lupus erythematosus (SLE).
methodsA total of 159 consecutive patients with SLE, diagnosed according to the American College of Rheumatology or Systemic Lupus International Collaborating Clinics classification criteria, were enrolled in CASTLE (Complement Activation Signatures in Systemic Lupus Erythematosus), a prospective observational study. Patients with 1-7 study visits were included in this longitudinal analysis. In addition, 48 healthy volunteers were enrolled to establish a normal reference value for the ratio of blood iC3b to serum C3 concentrations. Serum C3 and C4 levels were measured by nephelometry, and blood iC3b levels were measured by a lateral flow assay. SLE disease activity was monitored with the Responder Index 50 instrument of the SLE Disease Activity Index 2000.
resultsRelative changes in the iC3b:C3 ratio, levels of anti-double-stranded DNA (anti-dsDNA) antibodies, and use of a supraphysiologic dose of prednisone (>7.5 mg/day) each independently correlated with SLE disease activity, as determined in multilevel multiple logistic regression analyses. Only the iC3b:C3 ratio was significantly associated with clinically meaningful improvements in disease activity among patients with SLE who were receiving a supraphysiologic dose of prednisone. The iC3b:C3 ratio outperformed C3 and C4 levels with regard to discriminating active SLE from inactive SLE, and major flares from no disease activity. The iC3:C3 ratio, anti-dsDNA antibody levels, erythrocyte sedimentation rate, and use of a supraphysiologic prednisone dose were each independently associated with the presence of lupus nephritis, whereas none of these measures was associated with SLE rash. The association of the iC3b:C3 ratio with lupus nephritis was independent of other observed clinical manifestations.
conclusionThe ratio of blood iC3b to serum C3 concentrations correlates with the extent of SLE disease activity and with clinically meaningful changes in disease activity in patients with SLE. Furthermore, the iC3b:C3 ratio may discriminate between active and inactive SLE, and between major flares and no active disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.